The integration of PD-1 inhibitors into the therapeutic arsenal for LARC appears to enhance pCR rates significantly, offering a potential pathway for improved tumor downstaging and organ preservation strategies [14, 22]. This evidence concerns the gene PDCD1 and neoplasm.